Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by narinderon Jun 15, 2000 8:22pm

296 Views

Post# 2070525

Aquisition-COT undervalued @ $.42

For those of you who missed it...COT management was pretty clear in their article that a major aqusition is in the works...they were very clear in pointing out that this potential aquisition is of a company larger then them...this is the big news...once this transaction is complete we will see $.80+...remember it is not only daytraders involved in this one...institutional traders have been talking COT up as well...this combined with the excellent growth in the past quarter ads up to a very bright future for this company.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity